Article Sidebar

PDF
Date Published: 07/03/2023
Abstract Views: 344
Views PDF: 267
DOI: https://doi.org/10.51298/vmj.v523i2.4529
Issue
Vol. 523 No. 2 (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, V. T. . (2023). STUDY OF CLINICAL AND SUBCLINICAL FEATURES OF PATIENTS DIAGNOSED OF ADVANCED/ METASTATIC NON-SMALL CELL LUNG CANCER ACQUIRED RESISTED TO EGFR TKIS FIRST- AND SECOND-GENERATIONS. Vietnam Medical Journal, 523(2). https://doi.org/10.51298/vmj.v523i2.4529

STUDY OF CLINICAL AND SUBCLINICAL FEATURES OF PATIENTS DIAGNOSED OF ADVANCED/ METASTATIC NON-SMALL CELL LUNG CANCER ACQUIRED RESISTED TO EGFR TKIS FIRST- AND SECOND-GENERATIONS

Hùng Kiên Đỗ1,, Văn Tài Nguyễn1
1 National cancer hospital

Main Article Content

Abstract

Objective: Evaluating the rate of T790M mutation and analyzing the related factors of patients diagnosed of advanced/ metastatic non-small cell lung cancer acquired resistance to EGFR TKIs first- and second-generations at National Cancer Hospital from 01/2017 to 05/2022. Patients and method: Retrospective and prospective analysis of 85 patients with advanced/ metastatic non-small cell lung carcinoma acquired resistance to EGFR TKIs first- and second-generations were diagnosed and treated at National Cancer Hospital from 01/2017 to 05/2022. Results: Rate of acquired T790M mutation was 54.1%. Patients experienced progression-free survival more than 6 months had higher rate of T790M, there was a significant difference. There was non-significant difference between rates of acquired T790M and other features: age, gender, brain metastasis, type of EGFR mutations and type of targeted drugs. Conclusion: There was 54.1% of presence of acquired T790M muation in EGFR-positive non-small cell lung cancer patients treated with first- and second-generation tyrosine kinase.

Article Details

Keywords

Non-small cell lung cancer, resistance to EGFR TKIs, T790M mutation.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 2021, 71, 209–249, doi:10.3322/caac.21660.
2. Davis, F.; Dolecek, T.; Mccarthy, B.; Villano, J. Toward Determining the Lifetime Occurrence of Metastatic Brain Tumors Estimated from 2007 United States Cancer Incidence Data. Neuro-Oncol. 2012, 14, 1171–1177, doi:10.1093/neuonc/nos152.
3. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; et al. Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Lancet Oncol. 2012, 13, 239–246, doi:10.1016/S1470-2045(11)70393-X.
4. Mok, T.S.; Wu, Y.-L.; Thongprasert, S.; Yang, C.-H.; Chu, D.-T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957, doi:10.1056/NEJMoa0810699.
5. Sequist, L.V.; Yang, J.C.-H.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.-M.; Boyer, M.; et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J. Clin. Oncol. 2013, 31, 3327–3334, doi:10.1200/JCO.2012.44.2806.
6. Westover, D.; Zugazagoitia, J.; Cho, B.C.; Lovly, C.M.; Paz-Ares, L. Mechanisms of Acquired Resistance to First- and Second-Generation EGFR Tyrosine Kinase Inhibitors. Ann. Oncol. 2018, 29, i10–i19, doi:10.1093/annonc/mdx703.
7. Kobayashi, S.; Boggon, T.J.; Dayaram, T.; Jänne, P.A.; Kocher, O.; Meyerson, M.; Johnson, B.E.; Eck, M.J.; Tenen, D.G.; Halmos, B. EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2005, 352, 786–792, doi:10.1056/NEJMoa044238.
8. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLOS Med. 2005, 2, e73, doi:10.1371/journal.pmed.0020073.
9. Tseng JS, Su KY, Yang TY, et al. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M. Oncotarget. 2016;7(30):48059-48069. doi:10.18632/oncotarget.10351
10. Matsuo N, Azuma K, Sakai K, et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Sci Rep. 2016;6:36458. doi:10.1038/srep36458
11. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59. doi:10.1126/scitranslmed.3002356